Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Raccah

Showing results (1-10 of 80) with videos related to

Pageof 8
Sort By:
Diabetes, Obesity & Metabolism|July 17, 2008
Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitusD Raccah
Diabetes & Metabolism|January 9, 1999
[Physiopathology of diabetic neuropathies. Functional exploration of peripheral involvement]D Raccah
Archives Des Maladies Du Coeur Et Des Vaisseaux|January 24, 2007
[Management of diabetes in elderly cardiac patients]D Raccah
Diabetologia|March 14, 2007
Comment on: Evans JMM, Ogston SA, Emslie-Smith A, Morris AD (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930-936D Raccah
Diabetes & Metabolism|February 8, 2017
Basal insulin treatment intensification in patients with type 2 diabetes mellitus: A comprehensive systematic review of current optionsD Raccah
Diabetes & Metabolism|March 22, 2007
Importance of blood glucose management in the multifactorial approach of absolute cardiovascular risk in type 2 diabetes: the lessons from the Steno 2 studyD Raccah
Hormone Research|January 1, 1992
The syndrome of insulin resistanceP Vague, D Raccah
Presse Medicale (Paris, France : 1983)|December 4, 1993
[Place of insulin in atherothrombosis]P Vague, D Raccah
International Journal of Clinical Practice|February 7, 2009
Treating type 2 diabetes: how safe are current therapeutic agents?J Philippe, D Raccah
Diabetes & Metabolism|January 17, 2016
Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?P Darmon, D Raccah
Pageof 8

Showing results (1-10 of 80) with videos related to

Sort By:
Pageof 8
Diabetes, Obesity & Metabolism|July 17, 2008
Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitusD Raccah
Diabetes & Metabolism|January 9, 1999
[Physiopathology of diabetic neuropathies. Functional exploration of peripheral involvement]D Raccah
Archives Des Maladies Du Coeur Et Des Vaisseaux|January 24, 2007
[Management of diabetes in elderly cardiac patients]D Raccah
Diabetologia|March 14, 2007
Comment on: Evans JMM, Ogston SA, Emslie-Smith A, Morris AD (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930-936D Raccah
Diabetes & Metabolism|February 8, 2017
Basal insulin treatment intensification in patients with type 2 diabetes mellitus: A comprehensive systematic review of current optionsD Raccah
Diabetes & Metabolism|March 22, 2007
Importance of blood glucose management in the multifactorial approach of absolute cardiovascular risk in type 2 diabetes: the lessons from the Steno 2 studyD Raccah
Hormone Research|January 1, 1992
The syndrome of insulin resistanceP Vague, D Raccah
Presse Medicale (Paris, France : 1983)|December 4, 1993
[Place of insulin in atherothrombosis]P Vague, D Raccah
International Journal of Clinical Practice|February 7, 2009
Treating type 2 diabetes: how safe are current therapeutic agents?J Philippe, D Raccah
Diabetes & Metabolism|January 17, 2016
Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?P Darmon, D Raccah
Pageof 8